{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T21:10:08Z","timestamp":1772572208634,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.radonc.2023.109618","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T12:30:08Z","timestamp":1678710608000},"page":"109618","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease"],"prefix":"10.1016","volume":"183","author":[{"given":"Kewen","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chad","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4505-2280","authenticated-orcid":false,"given":"Duygu","family":"Sezen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4625-114X","authenticated-orcid":false,"given":"Livia","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurian","family":"Maleki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8832-0540","authenticated-orcid":false,"given":"Genevieve","family":"Bertolet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quynh-Nhu","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan I.","family":"Comeaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lily","family":"Schuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James W.","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.109618_b0005","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jama.2019.11058","article-title":"Systemic therapy for locally advanced and metastatic non-small cell lung cancer: A review","volume":"322","author":"Arbour","year":"2019","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.radonc.2023.109618_b0010","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1634\/theoncologist.12-7-864","article-title":"Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events","volume":"12","author":"Weber","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.radonc.2023.109618_b0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/OTT.S4833","article-title":"CTLA-4 blockade: therapeutic potential in cancer treatments","volume":"3","author":"Tarhini","year":"2010","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.radonc.2023.109618_b0020","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2023.109618_b0025","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109618_b0030","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2023.109618_b0035","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109618_b0040","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.ejso.2020.02.040","article-title":"Surgical treatment of stage IV colorectal cancer with synchronous liver metastases: A systematic review and network meta-analysis","volume":"46","author":"Ghiasloo","year":"2020","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.radonc.2023.109618_b0045","doi-asserted-by":"crossref","first-page":"S393","DOI":"10.1016\/j.jtho.2016.11.446","article-title":"MA09.05 Nivolumab alone or with ipilimumab in recurrent small cell lung cancer (SCLC): 2-Year survival and updated analyses from the checkmate 032 trial","volume":"12","author":"Hellmann","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2023.109618_b0050","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J Immunother"},{"key":"10.1016\/j.radonc.2023.109618_b0055","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-021-00261-6","article-title":"Liver metastases","volume":"7","author":"Tsilimigras","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.radonc.2023.109618_b0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092572","article-title":"Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model","volume":"9","author":"Yoshimoto","year":"2014","journal-title":"PLoS One."},{"key":"10.1016\/j.radonc.2023.109618_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0000000000000007","article-title":"CTLA-4 blockade enhances antitumor immunity of intratumoral injection of immature dendritic cells into irradiated tumor in a mouse colon cancer model","volume":"37","author":"Son","year":"2014","journal-title":"J Immunother"},{"key":"10.1016\/j.radonc.2023.109618_b0070","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","article-title":"Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment","volume":"92","author":"Kiess","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109618_b0075","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1158\/2326-6066.CIR-13-0082","article-title":"Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma","volume":"1","author":"Barker","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.radonc.2023.109618_b0080","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2023.109618_b0085","first-page":"5","article-title":"Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review","volume":"9","author":"Chicas-Sett","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.109618_b0090","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000627","article-title":"Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma","volume":"8","author":"Boutros","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.radonc.2023.109618_b0095","doi-asserted-by":"crossref","first-page":"558","DOI":"10.4049\/jimmunol.1200563","article-title":"Radiotherapy Promotes Tumor-Specific Effector CD8<sup>+<\/sup> T Cells via Dendritic Cell Activation","volume":"189","author":"Gupta","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.radonc.2023.109618_b0100","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1158\/2326-6066.CIR-18-0793","article-title":"Phase II trial of ipilimumab with stereotactic radiation therapy for metastatic disease: outcomes, toxicities, and low-dose radiation-related abscopal responses","volume":"7","author":"Welsh","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.radonc.2023.109618_b0105","doi-asserted-by":"crossref","first-page":"e101764-e","DOI":"10.1371\/journal.pone.0101764","article-title":"Focal radiation therapy combined with 4\u20131BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model","volume":"9","author":"Belcaid","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.radonc.2023.109618_b0110","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1158\/1078-0432.CCR-16-1432","article-title":"Ipilimumab with stereotactic ablative radiation therapy: Phase I results and immunologic correlates from peripheral T cells","volume":"23","author":"Tang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2023.109618_b0115","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","article-title":"Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer","volume":"11","author":"Demaria","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2023.109618_b0120","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to CTLA-4 blockade","volume":"24","author":"Formenti","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.radonc.2023.109618_b0125","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdt107","article-title":"Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I\/II study","volume":"24","author":"Slovin","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2023.109618_b0130","doi-asserted-by":"crossref","first-page":"e0157164","DOI":"10.1371\/journal.pone.0157164","article-title":"Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy","volume":"11","author":"Young","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.radonc.2023.109618_b0135","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2015.08.020","article-title":"Immunity, tolerance and autoimmunity in the liver: A comprehensive review","volume":"66","author":"Doherty","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1016\/j.radonc.2023.109618_b0140","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.lungcan.2015.02.012","article-title":"Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib","volume":"88","author":"Wu","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2023.109618_b0145","doi-asserted-by":"crossref","first-page":"53245","DOI":"10.18632\/oncotarget.10644","article-title":"Prognostic effect of liver metastasis in lung cancer patients with distant metastasis","volume":"7","author":"Ren","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2023.109618_b0150","doi-asserted-by":"crossref","first-page":"812210","DOI":"10.3389\/fimmu.2021.812210","article-title":"Novel Use of Low-Dose Radiotherapy to Modulate the Tumor Microenvironment of Liver Metastases","volume":"12","author":"He","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.radonc.2023.109618_b0155","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000537","article-title":"Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma","volume":"8","author":"Barsoumian","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.radonc.2023.109618_b0160","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.lungcan.2020.02.017","article-title":"Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases","volume":"142","author":"Corrao","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2023.109618_b0165","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/1756283X16685557","article-title":"Minimum absolute lymphocyte counts during radiation are associated with a worse prognosis in patients with unresectable hepatocellular carcinoma","volume":"10","author":"Zhao","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.radonc.2023.109618_b0170","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.radonc.2023.109618_b0175","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1470-2045(21)00658-6","article-title":"Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial","volume":"23","author":"Schoenfeld","year":"2022","journal-title":"Lancet Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023001561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023001561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:27:18Z","timestamp":1759123638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814023001561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":35,"alternative-id":["S0167814023001561"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109618","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109618","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109618"}}